Your Messages Inbox
Your Article Summary
See Latest ArticlesPhase 2 data from oral NKTR-118 presented at American College of Gastroenterology in San Diego
AstraZeneca, 10/28/09
Data from a phase II study demonstrated that oral NKTR–118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid–induced constipation, while simultaneously preserving opioid–mediated analgesia. NKTR–118, an oral peripherally–acting opioid antagonist, is an investigational product candidate in clinical development for the treatment of opioid–induced constipation.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor